title: The in vitro effect of a low molecular weight heparin, nadroparin (Fraxiparine), on leukocytes obtained from patients with vascular diseases.
abstract: BACKGROUND
  Both lymphocytes and granulocytes may play a role in the immune system-mediated inflammatory response associated with non-Q wave infarction and aortic aneurysms.
  
  
  METHODS
  The purpose of this study was to establish the in vitro effects of a low molecular weight heparin (LMWH), nadroparin (Fraxiparine), on some functional parameters of peripheral granulocytes and lymphocytes isolated from control subjects and patients with aortic aneurysm or non-Q wave infarction.
  
  
  RESULTS
  Nadroparin (0.06-600 AXaU/ml) exerted different in vitro effects on granulocytes and lymphocytes isolated from normal subjects and the patient groups. The following indices were assessed: superoxide anion release, lymphocyte proliferation, phagocytic activity and the cellular respiratory burst. The effects of nadroparin varied according to the patient group and the index of lymphocyte/granulocyte assessed.
  
  
  CONCLUSIONS
  Since peripheral granulocytes isolated from these patients are activated, the observed inhibition exerted by nadroparin on superoxide anion release may be beneficial. LMWHs have additional effects that are independent of their anticoagulant activity. These effects may influence the "inflammatory component" of the atherosclerotic process.
authors.affiliation: Immunobiology Department, Victor Babes Institute, Bucharest, Romania.
authors.forename: M
authors.initials: M
authors.lastname: Neagu
authors.forename: G
authors.initials: G
authors.lastname: Manda
authors.forename: C
authors.initials: C
authors.lastname: Constantin
authors.forename: C
authors.initials: C
authors.lastname: Tanaseanu
authors.forename: D P
authors.initials: DP
authors.lastname: Mikhailidis
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D017544:Aortic Aneurysm, Abdominal / Q000097:blood / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007962:Leukocytes / Q000187:drug effects*; D008214:Lymphocytes / Q000097:blood / Q000187:drug effects; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy; D017762:Nadroparin / Q000627:therapeutic use*; D009504:Neutrophils / Q000187:drug effects; D016491:Peripheral Vascular Diseases / Q000097:blood* / Q000188:drug therapy*; D012383:Romania
chemical_list: D000925:Anticoagulants; D017762:Nadroparin